Intensive cell communication in ADGRL4+ renal tubule cells might promote SFRP2+ renal tubule cells abundance and regulate prognosis of ccRCC patients, suggesting that targeting ADGRL4+ renal tubule cells might be a novel therapeutic direction for ccRCC treatment. This evidence concerns the gene SFRP2 and nonpapillary renal cell carcinoma.